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Introduction
More than two thousands of people around the world 
suffer from different types of kidney carcinoma with the 
highest prevalence in North America and Europe and 
the lowest in central Africa. Kidney cancer is the third 
common urologic cancer in Iran following bladder and 
prostate cancers (Akbari et al., 2005; Basiri et al., 2014). 
Also, a quarter of the affected patients face locally invasive 
or metastatic cancer (Jemal et al., 2005). In this regard, 
one-third of individuals with renal carcinoma undergo 
resection of localized disease may experience a recurrence. 
Hence, there is a great need for more effective surgical and 
medical therapies as well as accurate estimating survival 
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of the patients. Besides traditional risk factors for renal 
cell carcinoma including smoking, central obesity, existing 
kidney conditions, hepatitis infections, long-term use 
of non-steroidal anti inflammatory drugs, hypertension, 
low intake of fruits and vegetables, and family history 
of kidney cancer (Chow et al., 2000; Chow et al., 2010; 
Karami et al., 2013; Sanfilippo et al., 2014; Washio et al., 
2014), some genetic-based causes and mutations involved 
in protein over-expression and up-regulation have been 
recently identified to develop renal cell carcinoma 
(Moore et al., 2005; Haas et al., 2014). Moreover, the 
poor prognosis of cancer not only can be predicted by 
clinical (palpable abdominal mass) (Yap et al., 2013), 
some paraclinical factors (such as a high level of serum 
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lactate dehydrogenase, a low hemoglobin level, and a 
high corrected level of serum calcium), and histological 
factors (such as tumor staging, tumor grading, tumor size, 
degree of invasion and metastasis, histological type, and 
nuclear grade), but also the variants of gene mutations can 
be determinants for poor prognosis of the disease (Moch 
et al., 2013; Shuch et al., 2014). 
One of the recent investigated molecules studied that 
involved in gene mutational pathways for developing renal 
cell carcinoma is the P53 gene and its related specific 
protein (Uzunlar et al., 2005). The p53 protein accumulates 
at times of cellular or genotoxic stress, when it functions 
primarily as a transcription factor to promote cell cycle 
arrest and DNA repair, to initiate and maintain a senescent 
phenotype, or to promote apoptosis if the normal cellular 
conditions are not restored (Zigeuner et al., 2004). The 
importance of the tumor suppressor function of p53 is 
highlighted by the high frequency of tumors that occur 
in individuals with a monoallelic germline mutation of 
p53 (Kim et al., 2004). The potentially lethal activities 
of p53 are regulated by a proto-oncogene named MDM2 
(murine double minute 2). Several biological studies 
could demonstrated that p53 and MDM2 exist in an auto 
regulatory feedback loop that binding of MDM2 to p53 
can block p53 transcriptional activity by preventing it from 
interacting with the transcriptional machinery (Uchida 
et al., 2002; Kim et al., 2004). On the other hand, the 
increased levels of MDM2 can lead to a reduction in p53 
levels. With respect to cancer, MDM2 over expression has 
been associated with increased metastasis and advanced 
disease. 
Recently, the prognostic implications of both p53 
and MDM2 expression were more evaluated. It has been 
shown that the frequency of p53 mutations reported in 
a wide spectrum between 0% and 44% (Olumi et al., 
2001). Also, its value to assess prognosis and overall 
survival of caner is uncertain. It has been also observed 
that the expression of P53 may be linked to expression 
of MDM2 and thus higher prognostic value of expressing 
both molecules is also now hypothesized (Ljungberg et al., 
2001). However, relatively little is known with certainty 
about the status and role of p53 or MDM2 in predicting 
prognosis and survival of renal cell carcinoma. The present 
study aimed to determine the value of P53 and MDM2 
over-expression, alone and simultaneously, to predict five-
year survival of patients with kidney cancer.  
Materials and Methods
In a cohort study, patients with kidney cancer referred 
to Hasheminejad Kidney Center between 2007 and 2009, 
underwent radical nephrectomy and had pathology 
reports of clear cell, papillary or chromophobe renal cell 
carcinoma were included into the study. Other histological 
types of renal cell carcinoma were excluded from the 
study. Baseline characteristics regarding demographics, 
medical history, medications, and pathologic data included 
pTNM stage, tumor size, Fuhrman nuclear grade and the 
presence of vascular invasion were collected by reviewing 
the recorded files. The patients with missed, incomplete 
or poor quality paraffin blocks were also excluded from 
the study. Overall ninety one patients met the criteria.
For evaluation of immunohistochemical reactivity, 
representative areas from each case were selected from 
paraffin blocks based on hematoxylin and eosin-stained 
sections. IHC staining was carried out using an anti-p53 
monoclonal antibody (NOVOCASTRA clone DO-7, 
ready to use for immunohistochemistry) and anti-MDM2 
antibody (NOVOCASTRA clone 1B10 used at a dilution 
of 1:200 for immunohistochemistry). Both positive 
and negative control samples of both P53 and MDM2 
parameters were taken in every IHC examination. Breast 
cancer and well differentiated liposarcoma were used as 
positive controls and cerebellar tissue and pleomorphic 
liposarcoma for negative controls of P53 and MDM2 
respectively. All IHC slides were examined and scored 
by two pathologists independently and the mean were 
assigned. The intensity of nuclear immunostaining of 
P53 and MDM2 in individual tumor cells was scored on 
a scale of 0 (no staining), 1 (mild staining), 2 (moderate 
staining), and 3(strongest intensity), and the percentage 
of cells staining at each intensity was scored as 1 (0 to 
2 percent), 2 (3 to 10 percent), 3 (11 to 50 percent), and 
4 (more than 50 percent). Cases with intensity score of 
3 and percentage score of 4 were considered as positive. 
Other combinations of  intensity and percentage scores 
regarded as negative.
The five-year survival was determined by the patients’ 
medical files and telephone following-up. 
For analysis of our experience, results were presented 
as mean±standard deviation (SD) for quantitative 
variables and were summarized by absolute frequencies 
and percentages for categorical variables. Continuous 
variables were compared using t test, quantitative variables 
were, on the other hand, compared using chi-square test 
or Fisher’s exact test .Cancer-specific survival and overall 
survival were estimated using the Kaplan-Meier method, 
Multivariate Cox proportional hazards models using a 
backward stepwise selection method with the likelihood 
ratio criterion (inclusion/exclusion:P0.05/P.10) were 
used to determine the independent influence of variables 
on survival. All statistical tests were 2-sided and were 
performed at a significance level of 0.05. All analyses 
were performed using SPSS version 21.0 (SPSS Inc., 
Chicago, IL). 
Results 
Overall, ninety one patients were assessed. The mean 
age of patients was 56.7±12.3 years (ranged 28 to 86 
years) and 58.2% were male. The mean size of lesions 
was also 8.5±5.4 cm ranged 2.5 to 18cm. left-sided 
lesions were observed in 50.5% and right-sided in 49.5%. 
Regarding type of lesions, 69.2% were clear cell, 19.8% 
were chromophobe, and 11% were papillary. 15.1% 
were categorized as grade 1, 52% as grade 2, 27.0% 
as grade 3, and 6.2% as grade 4. With regard to organ 
involvement, renal sinus was involved in 71.3%, perirenal 
fat involvement in 23%, renal pelvis involvement in 7%, 
renal vein involvement in 9%, vena cava involvement in 
2.2% and adrenal gland involvement in 3.2%. Necrosis 
was noted in 51% of cases. Also, vascular and neural 
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invasions were observed in 23% and 3.3% respectively. 
Lymph node involvement was noted in 8%. Recurrence 
was revealed in 1.1%, while metastasis in 5-7 years follow 
up was occurred in 17.6%.
Regarding the intensity of immunostaining for anti-p53 
monoclonal antibody, the score was 0 in 82.4%, 1 in 7.7%, 
2 in 5.5%, and 3 in 4.4%. In this regard, the percentage 
of cells staining at intensity was scored as 1 in 78.0%, 
2 in 17.6%, 3 in 3.3%, and 4 in 1.1%. Thus, 1.1% of all 
samples were revealed to be positive for P53. Regarding 
intensity of immunostaining for anti-MDM2 antibody, the 
score was 0 in 31.9%, 1 in 17.6%, 2 in 19.8%, and 3 in 
30.8%. Also, the percentage of cells staining at intensity 
was scored as 1 in 33.0%, 2 in 12.1%, 3 in 29.7%, and 4 
in 25.3%. Thus, 20.8% of all samples were revealed to be 
positive for MDM2. Regarding risk factors, 14.3% were 
smoker and 12.1% were hypertensive. Regarding stage 
of disease, 18.6% had stage I, 5.4% had stage II, 69.2 % 
had stage III, and 6.5% had stage IV. 
The patients were all followed for 5 years survival. In 
this regard, 5-year mortality was 30.5% and thus 5-year 
survival was thus 5-year survival was 85.3%. There 
was no difference in 5-year survival between men and 
women (86.4% versus 83. 9%, p=0.834). The mean age 
of non-survivors was significantly higher than survivors 
(60.9±13.7 years versus 55.0±11.4 years, p=0.039). Also, 
5-year survival in clear type was Also, 5-year survival in 
clear type was 82%, in chromophobe type was 100%, and 
in papillary type was 77. 8% (p=0.014). 5-year survival 
rate was adversely associated with tumor grade (grade 1: 
90%, grade 2: 88.9%, grade 3: 76.5%, grade 4: 66.7%, 
p=0.001) and stage stage (stage I: 96.7%, stage II: 90.9%, 
stage III: 68.2%, stage IV: 0%, p=0.001). The higher 
intensity of immunostaining for anti-P53 antibody was 
Figure 1. Positive Controls for p53 and MDM2 (A) 
p53 Nuclear Positivity  in Invasive Ductal Carcinoma of Breast 
Cancer with Original Magnification ×20, (B) MDM2 Nuclear 
Positivity  in Well Differentiated Liposarcoma with Original 
Magnification ×20
Figure 2. Positive Nuclear Staining of p53 and MDM2 
in Renal Cell Carcinoma. (A) p53 Positive Immunoreaction 
with Original Magnification ×20, (B) MDM2 Positive 
Immunoreaction with Original Magnification ×20
Figure 3. Negative Nuclear Staining of p53 and MDM2 
in Renal Cell Carcinoma. (A) p53 Negative Immunoreaction 
with Original Magnification ×20, (B) MDM2 Negative 
Immunoreaction with Original Magnification ×20
Figure 4. Association of Intensity of Immunostaining 
for Anti-p53 Antibody with Survival
Table 1. Association of p53 Intensity with Survival
Intensity of p53 0 1 2 3
Survival
5-years 87.10% 80.10% 75% 60%
6-years 88.30% 71.40% 50% 75%
7-years 59.70% 71.40% 0% 0%
Figure 5. ROC Curve for p53 Showing Limited Role 
for Predicting Long-term Survival
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associated with lower 5-year survival (87.1% for score 
0, 80.1% for score 1, 75.0% for score 2, and 60.0% for 
score 3, p=0.008) (Figure 4) (Table 1), but no difference 
was found in 5-year survival between different scores 
for immunostaining for anti-MDM2 antibody (78.3% for 
score 0, 76.9% for score 1, 100% for score 2, and 87% 
for score 3, p=0.545) (Figure 5) (Table 2). According 
to the Cox proportional hazard analysis, positive P53 
marker was only predictor for patients’ 5-year survival 
that the presence of positive p53 increased the risk for 
long-term mortality up to 2.8 times (HR=2.798, 95%CI: 
1.176-6.660, P=0.020). However, the presence of MDM2 
could not predict long-term mortality. In this regard, 
analysis by the ROC curve (figure 6) showed a limited 
role for predicting long-term survival by confirming p53 
positivity (AUC=0.610, 95%CI: 0.471-.750, P=0.106). 
In this regard, the best cutoff point for P53 to predict 
mortality was 0.5 yielding a low sensitivity (32.0%) but 
a high specificity (97.9%). In similar analysis (figure 
7), measurement of MDM2 positivity could not predict 
mortality (AUC=0.449, 95%CI: 0.316-.583, P=0.455).
Discussion
The present study first aimed to determine the frequency 
of positive anti-P53 and also anti-MDM2 antibodies in 
patients who underwent radical nephrectomy leading a 
considerably low positivity of anti-P53 in 1.1%, but a 
positivity of anti-MDM2 in one-fifth of study subjects. 
However, only 1.1% of all subjects had positivity for both 
markers. Second, we showed that both indices could not 
predict long-term mortality and thus long-term survival 
in the patients. In this regard, analyzing area under the 
ROC curve was not resulted in a proper cutoff value of 
both P53 and MDM2 for predicting 5-year survival in the 
patients. On the other hand, the present scoring system 
for both biomarkers regarding intensity and percentage 
of the cells staining seems to be not useful for assessing 
long-term mortality in our population. In this regard, we 
did not achieve homogeneity of findings in Cox modeling 
and ROC curve analysis. 
Reviewing the literature reveals contradictory results. 
In a study (Hejnold et al., 2014), about 6.6% of patients 
were P53+/MDM2+ that was higher compared to our 
results as 1.1%. In another study (Noon et al., 2012), the 
presence of P53 but not its mutation was associated with 
reduced survival. Also, MDM2 expression was related 
to reduce survival. Other study (Polanski, 2010) showed 
that the concurrent expression of both p53 and MDM2 
was associated with considerably decreasing survival. In 
another research (Uchida et al., 2002) the expression of 
P53 and MDM2 was showed in 13.4% and 1.8% that was 
contrary to our finding. In that study, the expression of 
both markers could predict poor outcome in the patients. 
In other study (Haitel et al., 2000) study, simultaneous 
expression of both P53 and MDM2 was related to tumor 
progression. There is also a similar (Hashimoto et al., 
2000) that indicated that P53 could not predict disease 
outcome and thus only type of infiltration was predictor 
for poor outcome. Other research (Moch et al., 2013) also 
indicated positive P53 in 16% and positive MDM2 in 30% 
of subjects with a strong association between the two 
biomarkers and also with poor prognosis of the disease. In 
total, it seems that both P53 and MDM2 markers in Iranian 
population may not be able to predict long-term survival 
in patients who underwent radial nephrectomy that can be 
affected by genetic and racial differences. However, this 
claim should be assessed in further studies. 
In total, the simultaneous presence of both P53 and MDM2 
markers in our population is a rare phenomenon and the 
presence of these markers may not predict long-term 
survival in patients who undergoing radical nephrectomy. 
Future multicenter studies with larger sample size are 
required to show the prevalence of P53 and MDM2 
markers in Iranian population and association with long-
Figure 6. Association of Immunostaining for Anti-
MDM2 Antibody with Survival
Figure 6. ROC Curve for MDM2 Showing MDM2 
Positivity Could not Predict Survival
Table 2. Association of MDM2 Intensity with Survival
MDM2 intensity 0 1 2 3
Survival    
5-years 78.30% 76.90% 100.00% 87.00%
6-years 81.10% 80.20% 90.90% 88.60%
7-years 38.90% 50.90% 58.40% 63.20%
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term survival.
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